760 results on '"C. Albers"'
Search Results
2. Impact of different surgical and non-surgical interventions on health-related quality of life after thoracolumbar burst fractures without neurological deficit: A comprehensive systematic review with network meta-analysis
- Author
-
S. Bigdon, L. Lanter, G. Torbahn, P. Obid, J. Henssler, S. Kreuzer, C. Albers, N. Rutsch, and M. Müller
- Subjects
Neurology. Diseases of the nervous system ,RC346-429 - Published
- 2024
- Full Text
- View/download PDF
3. Anterior column reconstruction using a modular carbon-peek device: 28-case study over 18 months
- Author
-
S. Schaible, F. Aregger, S. Bigdon, L. Benneker, C. Albers, and M. Deml
- Subjects
Neurology. Diseases of the nervous system ,RC346-429 - Published
- 2024
- Full Text
- View/download PDF
4. Comparison of transiliac-transsacral screw fixation to lumbopelvic stabilization in the treatment of nondisplaced and minimally displaced sacral H-/U-type fragility fractures
- Author
-
J. Gewiess, Y.E. Roth, L. Benneker, P. Heini, and C. Albers
- Subjects
Neurology. Diseases of the nervous system ,RC346-429 - Published
- 2024
- Full Text
- View/download PDF
5. Taking a Breath of the Wild: are geoscientists more effective than non-geoscientists in determining whether video game world landscapes are realistic?
- Author
-
R. Hut, C. Albers, S. Illingworth, and C. Skinner
- Subjects
Geography. Anthropology. Recreation ,Science - Abstract
From the wilderness of Hyrule, the continent of Tamriel, and the geographies of Middle Earth, players of video games are exposed to wondrous, fantastic, but ultimately fake, landscapes. Given the time people may spend in these worlds compared to the time they spend being trained in geoscience, we wondered whether expert geoscientists would differ from non-geoscientists in whether they judge the landscapes in these video games to be “realistic”. Since video games present a great opportunity for tangential learning, it would be a missed opportunity if it turns out that features obviously fake to geoscientists are perceived as plausible by non-geoscientists. To satisfy our curiosity and answer this question, we conducted a survey where we asked people to judge both photos from real landscapes as well as screenshots from the recent The Legend of Zelda: Breath of the Wild video game on how likely they thought the features in the picture were to exist in the real world. Since game world screenshots are easily identified based on their rendered, pixelated nature, we pre-processed all pictures with an artistic “Van Gogh” filter that removed the rendered nature but retained the dominant landscape features. We found that there is a small but significant difference between geoscientists and non-geoscientists, with geoscientists being slightly better at judging which pictures are from the real world versus from the video game world. While significant, the effect is small enough to conclude that fantastical worlds in video games can be used for tangential learning on geoscientific subjects.
- Published
- 2019
- Full Text
- View/download PDF
6. Flooded by jargon: how the interpretation of water-related terms differs between hydrology experts and the general audience
- Author
-
G. J. Venhuizen, R. Hut, C. Albers, C. R. Stoof, and I. Smeets
- Subjects
Technology ,Environmental technology. Sanitary engineering ,TD1-1066 ,Geography. Anthropology. Recreation ,Environmental sciences ,GE1-350 - Abstract
Communication about water-induced hazards (such as floods, droughts or levee breaches) is important, in order to keep their impact as low as possible. However, sometimes the boundary between specialized and non-specialized language can be vague. Therefore, a close scrutiny of the use of hydrological vocabulary by both experts and laypeople is necessary. In this study, we compare the expert and layperson definitions of 22 common terms and pictures related to water and water hazards, to see where misunderstandings might arise both in text and pictures. Our primary objective is to analyze the degree of agreement between experts and laypeople in their definition of the used terms. In this way, we hope to contribute to improving the communication between these groups in the future. Our study was based on a survey completed by 34 experts and 119 laypeople. Especially concerning the definition of words related to water there are some profound differences between experts and laypeople: words like “river” and “river basin” turn out to have a thoroughly different interpretation between the two groups. Concerning the pictures, there is much more agreement between the groups.
- Published
- 2019
- Full Text
- View/download PDF
7. Neurocognitive functioning after Gamma Knife and LINAC stereotactic radiosurgery in patients with brain metastases
- Author
-
Elaine A. C. Albers, Michiel B. de Ruiter, Lonneke V. van de Poll-Franse, Laura G. Merckel, Annette Compter, Sanne B. Schagen, and Psychology Other Research (FMG)
- Subjects
Cancer Research ,Neurology ,Oncology ,Neurology (clinical) - Abstract
Purpose: Brain metastases (BM) themselves and treatment with stereotactic radiosurgery (SRS) can influence neurocognitive functioning. This prospective study aimed to assess neurocognitive decline in patients with BM after SRS. Methods: A neuropsychological test battery was assessed yielding ten test outcomes. Neurocognitive decline at 3 and 6 months post SRS was compared to measurement prior to Gamma Knife (GK) or linear accelerator (LINAC) SRS. Reliable change indices with correction for practice effects were calculated to determine the percentage of neurocognitive decline (defined as decline on ≥ 2 test outcomes). Risk factors of neurocognitive decline were analyzed with binary logistic regression. Results: Of 194 patients pre-SRS, 40 GK and 29 LINAC patients had data accessible at 6 months. Compared to baseline, 38% of GK patients declined at 3 months, and 23% declined at 6 months. GK patients declined on attention, executive functioning, verbal memory, and fine motor skill. Of LINAC patients, 10% declined at 3 months, and 24% at 6 months. LINAC patients declined on executive functioning, verbal memory, and fine motor skills. Risk factors of neurocognitive decline at 3 months were high age, low education level and type of SRS (GK or LINAC). At 6 months, high age was a risk factor. Karnofsky Performance Scale, BM volume, number of BM, tumor progression and neurocognitive impairment pre-SRS were no risk factors. Conclusion: Neurocognitive decline occurs in a considerable proportion of patients with BM treated with GK or LINAC SRS. Overall, high age appears to be a risk factor for neurocognitive decline after SRS.
- Published
- 2022
- Full Text
- View/download PDF
8. LUNG FUNCTION RESPONSE TO ALBUTEROL-BUDESONIDE VERSUS ALBUTEROL WHEN USED REPETITIVELY OVER 1 AND 4 WEEKS: RESULTS FROM THE DENALI STUDY
- Author
-
REYNOLD A PANETTIERI, BRADLEY E CHIPPS, RICHARD BEASLEY, ELLIOT ISRAEL, FRANK C ALBERS, JOHN BELL, CHRISTY CAPPELLETTI, ANNA DANILEWICZ, LYNN DUNSIRE, ILEEN GILBERT, PER GUSTAFSON, ROBERT REES, FRANK TRUDO, MARK WEINBERG, and ALBERTO PAPI
- Subjects
Pulmonary and Respiratory Medicine ,Cardiology and Cardiovascular Medicine ,Critical Care and Intensive Care Medicine - Published
- 2022
- Full Text
- View/download PDF
9. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)
- Author
-
M. Janning, J. Süptitz, C. Albers-Leischner, P. Delpy, A. Tufman, J.-L. Velthaus-Rusik, M. Reck, A. Jung, D. Kauffmann-Guerrero, I. Bonzheim, S. Brändlein, H.-D. Hummel, M. Wiesweg, H.-U. Schildhaus, J.A. Stratmann, M. Sebastian, J. Alt, J. Buth, I. Esposito, J. Berger, L. Tögel, F.C. Saalfeld, M. Wermke, S. Merkelbach-Bruse, A.M. Hillmer, F. Klauschen, C. Bokemeyer, R. Buettner, J. Wolf, S. Loges, Ronald Simon, Guido Sauter, Alexander Volk, Jens Neumann, Frederick Klauschen, Wilko Weichert, Naser Kalhori, Reinhard Lüthen, Robert Stöhr, Chistoph Schubart, Heidemarie Wacker, Florian Fuchs, Nils Hartmann, Stefanie Graf, Christian Brandts, Peter Wild, Melanie Demes, Henning Reis, and Gernot Rohde
- Subjects
ErbB Receptors ,Lung Neoplasms ,Treatment Outcome ,Genomic Medicine ,Oncology ,Carcinoma, Non-Small-Cell Lung ,Mutation ,Medizin ,Humans ,Hematology ,Protein Kinase Inhibitors ,respiratory tract diseases ,Retrospective Studies - Abstract
Background: Atypical EGFR mutations occur in 10%-30% of non-small-cell lung cancer (NSCLC) patients with EGFR mutations and their sensitivity to classical epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) is highly heterogeneous. Patients harboring one group of uncommon, recurrent EGFR mutations (G719X, S768I, L861Q) respond to EGFR-TKI. Exon 20 insertions are mostly insensitive to EGFR-TKI but display sensitivity to exon 20 inhibitors. Clinical outcome data of patients with very rare point and compound mutations upon systemic treatments are still sparse to date. Patients and methods: In this retrospective, multicenter study of the national Network Genomic Medicine (nNGM) in Germany, 856 NSCLC cases with atypical EGFR mutations including co-occurring mutations were reported from 12 centers. Clinical follow-up data after treatment with different EGFR-TKIs, chemotherapy and immune checkpoint inhibitors were available from 260 patients. Response to treatment was analyzed in three major groups: (i) uncommon mutations (G719X, S7681, L861Q and combinations), (ii) exon 20 insertions and (iii) very rare EGFR mutations (very rare single point mutations, compound mutations, exon 18 deletions, exon 19 insertions). Results: Our study comprises the largest thus far reported real-world cohort of very rare EGFR single point and compound mutations treated with different systemic treatments. We validated higher efficacy of EGFR-TKI in comparison to chemotherapy in group 1 (uncommon), while most exon 20 insertions (group 2) were not EGFR-TKI responsive. In addition, we found TKI sensitivity of very rare point mutations (group 3) and of complex EGFR mutations containing exon 19 deletions or L858R mutations independent of the combination partner. Notably, treatment responses in group 3 (very rare) were highly heterogeneous. Co-occurring TP53 mutations exerted a non-significant trend for a detrimental effect on outcome in EGFR-TKI-treated patients in groups 2 and 3 but not in group 1. Conclusions: Based on our findings, we propose a novel nNGM classification of atypical EGFR mutations.
- Published
- 2022
- Full Text
- View/download PDF
10. Albuterol/budesonide for the treatment of exercise-induced bronchoconstriction in patients with asthma
- Author
-
Laurence Reilly, Frank C. Albers, Alberto Papi, Bradley E. Chipps, Craig LaForce, Eva Johnsson, Christy Cappelletti, Helen Andrews, and Andrea Maes
- Subjects
Pulmonary and Respiratory Medicine ,Budesonide ,medicine.drug_class ,business.industry ,Immunology ,medicine.disease ,Placebo ,Metered-dose inhaler ,Crossover study ,respiratory tract diseases ,Anesthesia ,medicine ,Salbutamol ,Immunology and Allergy ,Corticosteroid ,Bronchoconstriction ,medicine.symptom ,business ,Asthma ,medicine.drug - Abstract
Background PT027 is a fixed-dose combination of albuterol (salbutamol) and budesonide in a single pressurized metered dose inhaler. Objective To assess the efficacy and safety of albuterol/budesonide compared with placebo in patients with asthma and exercise-induced bronchoconstriction (EIB). Methods In this randomized, double-blind, 2-period, single-dose crossover study, adolescents and adults with asthma and EIB (defined by ≥20% decrease from pre-exercise challenge FEV 1) were randomized to albuterol/budesonide (180/160 µg) followed by placebo (n=29) or the reverse sequence (n=31). Subjects were stratified by background therapy (as-needed short-acting β 2 -agonist [SABA] alone or low- to medium-dose inhaled corticosteroid [ICS] plus as-needed SABA). FEV 1 was measured 5 minutes pre-dose, 30 minutes post-dose (5 minutes pre-exercise challenge [baseline]), and 5, 10, 15, 30 and 60 minutes post-exercise. The primary endpoint was maximum percentage fall from baseline in FEV 1 up to 60 minutes postexercise challenge. Results Least squares mean maximum percentage fall in FEV 1 up to 60 minutes postexercise challenge was 5.45% with albuterol/budesonide versus 18.97% with placebo (difference -13.51% [95% CI: -16.94%, -10.09%]; p Conclusion In adolescents and adults with asthma and EIB, a single dose of albuterol/budesonide 180/160 µg taken approximately 30 minutes prior to exercise was significantly more effective than placebo in preventing EIB.
- Published
- 2022
- Full Text
- View/download PDF
11. Supplemental Table 2 from The Cyclic AMP Pathway Is a Sex-Specific Modifier of Glioma Risk in Type I Neurofibromatosis Patients
- Author
-
Joshua B. Rubin, David H. Gutmann, Joshua D. Schiffman, Jeffrey C. Allen, Uri Tabori, Michael J. Fisher, Karlyne M. Reilly, Jason T. Forys, Todd E. Druley, David Viskochil, David A. Stevenson, Douglas R. Stewart, Amanda Merkelson, Anne C. Albers, Debra Spoljaric, Sara Ganzhorn, Patricia C. Parkin, Robert C. McKinstry, Jingqin Luo, Tao Sun, and Nicole M. Warrington
- Abstract
Supplemental Table 2: List of SNPs analyzed.
- Published
- 2023
- Full Text
- View/download PDF
12. Supplemental Table 3 from The Cyclic AMP Pathway Is a Sex-Specific Modifier of Glioma Risk in Type I Neurofibromatosis Patients
- Author
-
Joshua B. Rubin, David H. Gutmann, Joshua D. Schiffman, Jeffrey C. Allen, Uri Tabori, Michael J. Fisher, Karlyne M. Reilly, Jason T. Forys, Todd E. Druley, David Viskochil, David A. Stevenson, Douglas R. Stewart, Amanda Merkelson, Anne C. Albers, Debra Spoljaric, Sara Ganzhorn, Patricia C. Parkin, Robert C. McKinstry, Jingqin Luo, Tao Sun, and Nicole M. Warrington
- Abstract
Supplemental Table 3. Primer sequences.
- Published
- 2023
- Full Text
- View/download PDF
13. Supplemental Table 1 from The Cyclic AMP Pathway Is a Sex-Specific Modifier of Glioma Risk in Type I Neurofibromatosis Patients
- Author
-
Joshua B. Rubin, David H. Gutmann, Joshua D. Schiffman, Jeffrey C. Allen, Uri Tabori, Michael J. Fisher, Karlyne M. Reilly, Jason T. Forys, Todd E. Druley, David Viskochil, David A. Stevenson, Douglas R. Stewart, Amanda Merkelson, Anne C. Albers, Debra Spoljaric, Sara Ganzhorn, Patricia C. Parkin, Robert C. McKinstry, Jingqin Luo, Tao Sun, and Nicole M. Warrington
- Abstract
Supplemental Table 1: Specimen Characteristics.
- Published
- 2023
- Full Text
- View/download PDF
14. Albuterol-Budesonide Pressurized Metered Dose Inhaler in Patients With Mild-to-moderate Asthma
- Author
-
Bradley E. Chipps, Elliot Israel, Richard Beasley, Reynold A. Panettieri, Frank C. Albers, Robert Rees, Lynn Dunsire, Anna Danilewicz, Eva Johnsson, Christy Cappelletti, and Alberto Papi
- Subjects
Pulmonary and Respiratory Medicine ,Cardiology and Cardiovascular Medicine ,Critical Care and Intensive Care Medicine - Published
- 2023
- Full Text
- View/download PDF
15. Mepolizumab improves work productivity, activity limitation, symptoms, and rescue medication use in severe eosinophilic asthma
- Author
-
Frank C. Albers, Daniel J. Bratton, Necdet B. Gunsoy, Sarah M. Cockle, Rafael Alfonso‐Cristancho, and Gert‐Jan Braunstahl
- Subjects
Pulmonary and Respiratory Medicine ,Treatment Outcome ,Double-Blind Method ,Humans ,Immunology and Allergy ,Anti-Asthmatic Agents ,Antibodies, Monoclonal, Humanized ,Severity of Illness Index ,Asthma ,Genetics (clinical) ,Randomized Controlled Trials as Topic - Abstract
Patients with severe eosinophilic asthma experience daily activity limitations and reduced productivity at work. Using anonymized individual patient-level data from two previously conducted randomized, double-blind, placebo-controlled studies (MENSA [GSK ID:115588/NCT01691521]; MUSCA [GSK ID:200862/NCT02281318]), we investigated the effect of mepolizumab on work productivity, activity limitation, symptoms, and rescue medication use. Patient-reported outcomes including Work Productivity and Activity Impairment-General Health (WPAI-GH) scores (impairment percentages, 0%-100%), global activity limitation (scale 1-4), and perceived change in activity limitation (Likert scale 1-7) since the start of the study were analyzed. WPAI-GH scores from MENSA were analyzed post hoc for employed patients using mixed model repeated measures; global activity limitation and perceived change in activity limitation from MUSCA were analyzed by ordinal logistic regression. Mean changes from baseline in daily asthma symptom scores (scale 0-5) and rescue medication use (occasions/day) were also assessed, via a post hoc meta-analysis of MENSA and MUSCA. At study end, WPAI-GH scores indicative of overall work impairment, impairment while working, and activity impairment consistently improved with mepolizumab versus placebo. Overall, 76% versus 54% of patients rated their activity as "much better," "better," or "slightly better" since the start of the study with mepolizumab versus placebo. Mepolizumab was associated with numerically larger improvements from baseline in asthma symptoms (treatment difference 0.21-0.29 points) and rescue medication use (treatment difference -0.08 to -0.22 occasions/day) versus placebo. Our results indicate that patients with severe eosinophilic asthma may experience improved activity limitation, work productivity, symptoms, and rescue medication use with mepolizumab.
- Published
- 2022
- Full Text
- View/download PDF
16. Single-Day Low-Residue Diet Prior to Colonoscopy Demonstrates Improved Bowel Preparation Quality and Patient Tolerance over Clear Liquid Diet: A Randomized, Single-Blinded, Dual-Center Trial
- Author
-
Kenneth J. Chang, Elise Tran, Daniel Thieu, Allen R. Yu, William E. Karnes, Nimisha K. Parekh, Alexander Abadir, Nabil El Hage Chehade, Gregory C. Albers, M. Mazen Jamal, Jason B. Samarasena, and Daniel Mai
- Subjects
medicine.medical_specialty ,Evening ,medicine.diagnostic_test ,Physiology ,business.industry ,Nausea ,Gastroenterology ,Colonoscopy ,03 medical and health sciences ,0302 clinical medicine ,Bloating ,Patient satisfaction ,Tolerability ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Vomiting ,Low residue diet ,030211 gastroenterology & hepatology ,medicine.symptom ,business - Abstract
Patients often refer to bowel preparation and associated dietary restrictions as the greatest deterrents to having a colonoscopy completed or performed. Large studies comparing a low-residue diet (LRD) and a clear liquid diet (CLD) are still limited. The aim of this study is to compare LRD and CLD with regard to bowel preparation quality, tolerance, and satisfaction among a diverse patient population. This study is a dual-center, randomized, single-blinded, prospective trial involving adult patients undergoing outpatient colonoscopy at the University of California Irvine Medical Center and an affiliated Veterans Administration hospital. Patients were randomized to consume either a CLD or a planned LRD for the full day prior to colonoscopy. Both groups consumed 4L split-dosed PEG-ELS. The adequacy of bowel preparation was evaluated using the Boston Bowel Preparation Score (BBPS). Adequate preparation was defined as a BBPS ≥ 6 with no individual segment less than a score of 2. Hunger and fatigue pre - and post-procedure were graded on a ten-point scale. Nausea, vomiting, bloating, abdominal cramping, overall discomfort, satisfaction with the diet, willingness to repeat the same preparation and overall experience were assessed. A total of 195 subjects who underwent colonoscopy from October 2014 to October 2017 were included. The mean BBPS for the LRD and CLD groups was 8.38 and 7.93, respectively (p = 0.1). There was a significantly higher number of adequate preparations in the LRD group compared to CLD (p = 0.05). Evening hunger scores just before starting the bowel preparation were significantly lower in the LRD than the CLD group, 2.81 versus 5.97, respectively (p = 0.006). Subjects in the LRD group showed significantly less nausea (p = 0.047) and bloating (p = 0.04). Symptom scores for vomiting, abdominal cramping, and overall discomfort were similar between the groups. Satisfaction with diet was significantly higher in the LRD group than CLD, 72% versus 37.66%, respectively (p
- Published
- 2021
- Full Text
- View/download PDF
17. Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials
- Author
-
Steven W. Yancey, Catherine Lemière, Mark C. Liu, Camille Taillé, Frank C. Albers, Jason Kihyuk Lee, Steven G. Smith, Stephen Mallett, and Eric S. Bradford
- Subjects
medicine.medical_specialty ,Phase iii trials ,Post hoc ,Health-related quality of life ,Immunology ,Antibodies, Monoclonal, Humanized ,Placebo ,Severity of Illness Index ,Exacerbations ,Airway reversibility ,03 medical and health sciences ,Diseases of the respiratory system ,0302 clinical medicine ,Forced Expiratory Volume ,Internal medicine ,Asthma control ,medicine ,Clinical endpoint ,Immunology and Allergy ,Humans ,030212 general & internal medicine ,Respiratory system ,Baseline (configuration management) ,Mepolizumab ,Randomized Controlled Trials as Topic ,Asthma ,RC705-779 ,business.industry ,Research ,medicine.disease ,Allergen sensitivity ,Lung function ,Respiratory Function Tests ,respiratory tract diseases ,Clinical Trials, Phase III as Topic ,030228 respiratory system ,Asthma Control Questionnaire ,Meta-analysis ,Disease Progression ,Airway ,business ,medicine.drug - Abstract
Background Severe asthma is associated with a broad range of phenotypes and clinical characteristics. This analysis assessed whether select baseline patient characteristics could prognosticate mepolizumab efficacy in severe eosinophilic asthma. Methods This was a post hoc meta-analysis of data from the Phase III MENSA (NCT01691521/MEA115588) and MUSCA (NCT02281318/200862) studies. Patients aged ≥ 12 years with severe eosinophilic asthma and a history of exacerbations were randomised to receive placebo (MENSA/MUSCA), mepolizumab 75 mg intravenously (MENSA) or 100 mg subcutaneously (SC) (MENSA/MUSCA) every 4 weeks for 32 (MENSA) or 24 (MUSCA) weeks. The primary endpoint was the annual rate of clinically significant exacerbations; other outcomes included the proportion of patients with no exacerbations and changes from baseline in pre-bronchodilator forced expiratory volume in 1 s (FEV1), St George’s Respiratory Questionnaire (SGRQ) total score and Asthma Control Questionnaire (ACQ)-5 score. Analyses were performed by baseline age of asthma onset (1 ≤ 60; 60–80; > 80); airway reversibility (reversible [≥ 12% change in FEV1]; non-reversible [1]); perennial and/or seasonal allergen sensitivity (yes/no); asthma control (uncontrolled [ACQ-5 score ≥ 1.5]; partial/complete control [ACQ-5 score Results Overall, 936 patients received mepolizumab 100 mg SC or placebo. Across age at asthma onset, lung function and airway reversibility subgroups, mepolizumab reduced the rate of clinically significant exacerbations by 49–63% versus placebo. Improvements in lung function, SGRQ total score and ACQ-5 score were also seen with mepolizumab versus placebo across most age and lung function subgroups. Clinically significant exacerbations were reduced with mepolizumab versus placebo irrespective of season or allergen sensitivity; SGRQ total and ACQ-5 scores were generally improved across seasons. Conclusions Mepolizumab efficacy was consistent for patients with varying age at asthma onset, lung function, airway reversibility and allergen sensitivities at baseline. Our results indicate that mepolizumab is likely to be beneficial for patients with severe eosinophilic asthma with a broad range of baseline clinical characteristics; large-scale real-world studies are needed to confirm the external validity of these findings. Trial registration Post hoc meta-analysis of data from MENSA (NCT01691521/MEA115588) and MUSCA (NCT02281318/200862)
- Published
- 2021
18. LUNG FUNCTION RESPONSE TO ALBUTEROL-BUDESONIDE VERSUS ALBUTEROL WHEN USED REPETITIVELY OVER 1 AND 4 WEEKS: RESULTS FROM THE DENALI STUDY
- Author
-
PANETTIERI, REYNOLD A, primary, E CHIPPS, BRADLEY, additional, BEASLEY, RICHARD, additional, ISRAEL, ELLIOT, additional, C ALBERS, FRANK, additional, BELL, JOHN, additional, CAPPELLETTI, CHRISTY, additional, DANILEWICZ, ANNA, additional, DUNSIRE, LYNN, additional, GILBERT, ILEEN, additional, GUSTAFSON, PER, additional, REES, ROBERT, additional, TRUDO, FRANK, additional, WEINBERG, MARK, additional, and PAPI, ALBERTO, additional
- Published
- 2022
- Full Text
- View/download PDF
19. Brown Bowel Syndrome Is a Rare and Commonly Missed Disease: A Case Report and Literature Review
- Author
-
Xiaodong Li, Daniel Moon Kim, Vishal S. Chandan, Wenchang Guo, Gregory C. Albers, Joaquin Ponce-Zepeda, and Giorgioni Carmen
- Subjects
History ,medicine.medical_specialty ,Abdominal pain ,Polymers and Plastics ,Adhesion (medicine) ,RC799-869 ,Asymptomatic ,Gastroenterology ,Industrial and Manufacturing Engineering ,03 medical and health sciences ,0302 clinical medicine ,Bloating ,Internal medicine ,Biopsy ,medicine ,Business and International Management ,medicine.diagnostic_test ,business.industry ,Diseases of the digestive system. Gastroenterology ,medicine.disease ,Bowel obstruction ,030220 oncology & carcinogenesis ,Etiology ,Vitamin E deficiency ,medicine.symptom ,business ,030217 neurology & neurosurgery - Abstract
Background. Brown bowel syndrome (BBS) is a rare gastrointestinal condition, and vitamin E deficiency has been considered to be a main contributor. However, vitamin E deficiency has been found in only a few patients throughout the published literature studies and its cutoff lab value for diagnosis is not entirely clarified. Case Presentation. A 56-year-old female patient with a history of congenital bowel obstruction (repaired at birth) presented with bloating, abdominal pain, and chronic diarrhea. Endoscopy identified unremarkable gastrointestinal mucosa except a few small polyps in the colon. A partial obstruction was detected by a small bowel follow-through series and then confirmed by CT scan. The resected small bowel was significantly dilated with a thickened brown wall and extensive serosal adhesion. Microscopic examination revealed unremarkable mucosa, but dense granular brown pigments were identified in the cytoplasm of the smooth muscle cells in the muscularis propria. These deposits resulted to be lipofuscin, and BBS was diagnosed. The patient was asymptomatic at 9-month follow-up after surgery without vitamin E supplement. Conclusion. Mitochondrial damage with lipofuscin deposition is at the root of BBS pathogenesis. Any etiology associated with mitochondrial damage can cause this disease, and vitamin E deficiency is just one of them. Dysmotility from extensive serosal adhesion could be a possible etiology for this patient. Due to overlapping symptoms, lipofuscin deposition primarily in the muscularis propria, and unclear serum value of vitamin E, this syndrome is often missed in routine clinical practice from the superficial biopsy. A transmural biopsy is necessary for a definite diagnosis.
- Published
- 2021
- Full Text
- View/download PDF
20. Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies
- Author
-
Bhabita Mayer, Choon-Sik Park, Mi-Kyeong Kim, Nam-Hee Kwon, Hae-Sim Park, Soung-Jun Min, Frank C. Albers, and Steven W. Yancey
- Subjects
medicine.medical_specialty ,Pulmonology ,Population ,Antibodies, Monoclonal, Humanized ,Placebo ,03 medical and health sciences ,0302 clinical medicine ,republic of korea ,Internal medicine ,Post-hoc analysis ,therapeutics ,medicine ,Humans ,Anti-Asthmatic Agents ,Child ,education ,Adverse effect ,Asthma ,education.field_of_study ,business.industry ,asthma ,medicine.disease ,symptom flare up ,Clinical trial ,Asthma Control Questionnaire ,Medicine ,Original Article ,030211 gastroenterology & hepatology ,business ,Mepolizumab ,medicine.drug - Abstract
Background/aims The efficacy and safety of mepolizumab in patients with severe eosinophilic asthma has been evaluated in a global clinical trial programme. This post hoc analysis assesses the efficacy and safety of mepolizumab in Korean patients. Methods Data from Korean patients in the Phase III, placebo-controlled, randomised DREAM (MEA112997/NCT01000506) and MENSA (MEA115588/ NCT01691521) studies were included. Patients ≥ 12 years old with severe eosinophilic asthma received mepolizumab (DREAM: 75, 250 or 750 mg intravenously [IV]; MENSA: 75 mg IV or 100 mg subcutaneously [SC]), or placebo every 4 weeks for 52 weeks (DREAM) or 32 weeks (MENSA). The primary outcome was the rate of clinically significant asthma exacerbations. Secondary outcomes included forced expiratory volume in 1 second (FEV1), Asthma Control Questionnaire (ACQ) and St George's Respiratory Questionnaire (SGRQ) scores (MENSA only). Blood eosinophil counts (BEC) and safety were assessed throughout. Results Reductions in the rate of clinically significant asthma exacerbations were observed with the approved (100 mg SC) and bioequivalent (75 mg IV) doses of mepolizumab in Korean patients who participated in DREAM and MENSA. In MENSA, trends for improvements from baseline at week 32 in pre-bronchodilator FEV1 (75 mg IV group), ACQ-5 and SGRQ scores (in both treatment groups) were seen versus placebo in Korean patients. Incidence of on-treatment adverse events was similar in Korean patients versus non-Korean patients as were observed reductions from baseline in BEC. Conclusions Mepolizumab treatment provided clinical benefits for Korean patients with severe eosinophilic asthma; the safety profile is consistent with the overall population.
- Published
- 2021
- Full Text
- View/download PDF
21. Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma
- Author
-
Alberto Papi, Bradley E. Chipps, Richard Beasley, Reynold A. Panettieri, Elliot Israel, Mark Cooper, Lynn Dunsire, Allison Jeynes-Ellis, Eva Johnsson, Robert Rees, Christy Cappelletti, and Frank C. Albers
- Subjects
Asthma, albuterol-budesonide fixed-dose combination, short-acting β2-agonist (SABA), severe asthma exacerbation ,Adult ,Adolescent ,Nebulizers and Vaporizers ,severe asthma exacerbation ,Socio-culturale ,General Medicine ,Symptom Flare Up ,Asthma ,Maintenance Chemotherapy ,Drug Combinations ,Young Adult ,Double-Blind Method ,Ethanolamines ,Child, Preschool ,Formoterol Fumarate ,Administration, Inhalation ,Humans ,Albuterol ,short-acting β2-agonist (SABA) ,Budesonide ,Child ,Glucocorticoids ,albuterol-budesonide fixed-dose combination - Abstract
As asthma symptoms worsen, patients typically rely on short-acting βWe conducted a multinational, phase 3, double-blind, randomized, event-driven trial to evaluate the efficacy and safety of albuterol-budesonide, as compared with albuterol alone, as rescue medication in patients with uncontrolled moderate-to-severe asthma who were receiving inhaled glucocorticoid-containing maintenance therapies, which were continued throughout the trial. Adults and adolescents (≥12 years of age) were randomly assigned in a 1:1:1 ratio to one of three trial groups: a fixed-dose combination of 180 μg of albuterol and 160 μg of budesonide (with each dose consisting of two actuations of 90 μg and 80 μg, respectively [the higher-dose combination group]), a fixed-dose combination of 180 μg of albuterol and 80 μg of budesonide (with each dose consisting of two actuations of 90 μg and 40 μg, respectively [the lower-dose combination group]), or 180 μg of albuterol (with each dose consisting of two actuations of 90 μg [the albuterol-alone group]). Children 4 to 11 years of age were randomly assigned to only the lower-dose combination group or the albuterol-alone group. The primary efficacy end point was the first event of severe asthma exacerbation in a time-to-event analysis, which was performed in the intention-to-treat population.A total of 3132 patients underwent randomization, among whom 97% were 12 years of age or older. The risk of severe asthma exacerbation was significantly lower, by 26%, in the higher-dose combination group than in the albuterol-alone group (hazard ratio, 0.74; 95% confidence interval [CI], 0.62 to 0.89; P = 0.001). The hazard ratio in the lower-dose combination group, as compared with the albuterol-alone group, was 0.84 (95% CI, 0.71 to 1.00; P = 0.052). The incidence of adverse events was similar in the three trial groups.The risk of severe asthma exacerbation was significantly lower with as-needed use of a fixed-dose combination of 180 μg of albuterol and 160 μg of budesonide than with as-needed use of albuterol alone among patients with uncontrolled moderate-to-severe asthma who were receiving a wide range of inhaled glucocorticoid-containing maintenance therapies. (Funded by Avillion; MANDALA ClinicalTrials.gov number, NCT03769090.).
- Published
- 2022
22. Response to mepolizumab treatment is sustained across 4-weekly dosing periods
- Author
-
Daniel J. Bratton, Frank C. Albers, Ian D. Pavord, Roland Buhl, Eugene R. Bleecker, Pascal Chanez, Elisabeth H. Bel, Steven W. Yancey, and Peter H. Howarth
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Exacerbation ,business.industry ,lcsh:R ,lcsh:Medicine ,Eosinophilic asthma ,Original Articles ,Placebo ,Asthma ,Treatment period ,03 medical and health sciences ,0302 clinical medicine ,030228 respiratory system ,Internal medicine ,Post-hoc analysis ,Medicine ,In patient ,030212 general & internal medicine ,Dosing ,business ,Mepolizumab ,medicine.drug - Abstract
Background Mepolizumab (100 mg delivered s.c. every 4 weeks) is indicated for add-on maintenance treatment for patients with severe eosinophilic asthma. Mepolizumab has been shown to reduce exacerbations and the requirement for daily oral corticosteroids, and improve asthma control and symptoms. However, data on the durability of the response to mepolizumab during dosing periods are limited. The aim of this study was to investigate the efficacy profile in patients with severe eosinophilic asthma over the 4-weekly dosing period for various fixed mepolizumab doses. Methods This was a post hoc analysis of data from the phase IIb/III DREAM study. Patients ≥12 years of age with severe eosinophilic asthma were randomised (1:1:1:1) to receive intravenous mepolizumab 75 mg (equivalent to 100 mg s.c.), 250 mg, 750 mg or placebo, plus standard of care, every 4 weeks for 52 weeks. The number of exacerbations and eDiary data (peak expiratory flow, rescue medication use and symptom scores) from two periods in each 4-weekly dosing interval (days 1–14 and 15–28) over the 52-week treatment period were analysed. Findings eDiary data and the proportion of patients experiencing ≥1 exacerbation were similar during the first and second 2 weeks of a dosing period across all mepolizumab doses. Interpretation These results demonstrate that the response to mepolizumab is sustained over the 4-weekly dosing period with no differences across a 10-fold dose range and supports the use of the current mepolizumab dosing regimen in patients with severe eosinophilic asthma., Post hoc analysis of data from DREAM demonstrated a sustained response to mepolizumab across the 4-weekly dosing period, suggesting therapeutic benefit is maintained between each mepolizumab dose following long-term treatment https://bit.ly/3843lH6
- Published
- 2020
- Full Text
- View/download PDF
23. Oral IBGard™ Before Colonoscopy: A Single-Center Double-Blinded, Randomized, Placebo-Controlled Trial
- Author
-
William E. Karnes, Erica Duh, Zain Moosvi, Sunhee Park, James Y. Han, Gregory C. Albers, and Jason B. Samarasena
- Subjects
medicine.diagnostic_test ,Physiology ,business.industry ,medicine.medical_treatment ,Gastroenterology ,Placebo-controlled study ,Colonoscopy ,Single Center ,Placebo ,Polypectomy ,law.invention ,stomatognathic diseases ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,Oral administration ,law ,030220 oncology & carcinogenesis ,Anesthesia ,Medicine ,Intubation ,030211 gastroenterology & hepatology ,business - Abstract
Peppermint oil is well known to inhibit smooth muscle contractions, and its topical administration during colonoscopy is reported to reduce colonic spasms. We aimed to assess whether oral administration of IBGard™, a sustained-release peppermint oil formulation, before colonoscopy reduces spasms and improves adenoma detection rate (ADR). We performed a single-center randomized, double-blinded, placebo-controlled trial. Patients undergoing screening or surveillance colonoscopies were randomized to receive IBGard™ or placebo. The endoscopist graded spasms during insertion, inspection, and polypectomy. Bowel preparation, procedure time, and time of drug administration were documented. Statistical analysis was performed using the Student’s t test and Wilcoxon rank-sum test. There was no significant difference in baseline characteristics or dose-timing distribution between IBGard™ and placebo groups. Similarly, there was no difference in ADR (IBGard™ = 47.8%, placebo = 43.1%, p = 0.51), intubation spasm score (1.23 vs 1.2, p = 0.9), withdrawal spasm score (1.3 vs 1.23, p = 0.72), or polypectomy spasm score (0.52 vs 0.46, p = 0.69). Limiting the analysis to patients who received the drug more than 60 min prior to the start of the procedure did not produce any significant differences in these endpoints. This randomized controlled trial failed to show benefit of orally administered IBGard™ prior to colonoscopy on the presence of colonic spasms or ADR. Because of its low barrier to widespread adoption, the use of appropriately formulated and timed oral peppermint oil warrants further study to determine its efficacy in reducing colonic spasms and improving colonoscopy quality.
- Published
- 2020
- Full Text
- View/download PDF
24. Parameter sensitivity analysis of a two-dimensional cryo-hydrogeological numerical model of degrading permafrost near Umiujaq (Nunavik, Canada)
- Author
-
Britt M. C. Albers, John Molson, and Victor F. Bense
- Subjects
geography ,geography.geographical_feature_category ,Hydrogeology ,010504 meteorology & atmospheric sciences ,Groundwater flow ,Bedrock ,0208 environmental biotechnology ,Soil science ,02 engineering and technology ,Silt ,Permafrost ,01 natural sciences ,020801 environmental engineering ,Heat flux ,Heat exchanger ,Earth and Planetary Sciences (miscellaneous) ,Environmental science ,Sensitivity (control systems) ,0105 earth and related environmental sciences ,Water Science and Technology - Abstract
A calibrated field-scale numerical model of groundwater flow and permafrost degradation has been used in a sensitivity analysis of permafrost thaw on thermal and hydraulic parameters. The two-dimensional cryo-hydrogeological model was developed using the HEATFLOW-SMOKER code applied to the Umiujaq field site in Nunavik, Quebec, Canada, and includes coupled groundwater flow and advective–conductive heat transport with latent-heat and temperature-dependent thermal and hydraulic properties. Model sensitivity was evaluated by using the PEST code to systematically vary selected thermal and hydraulic parameters, and was quantified with respect to three system output variables or ‘targets’: subsurface temperature, groundwater velocity and ground-surface heat flux. PEST-derived model sensitivities were similar for all targets which contained subsurface temperature profiles, while sensitivities were slightly higher when only summer conditions were considered as the target compared to a full year of data. This trend was attributed to greater heat exchange at the ground surface during the summer months, leading to a more active groundwater flow system and greater feedback to the thermal regime. For all targets, the hydraulic and thermal parameters of the shallow layers (fine sand and marine silt, respectively) as well as the parameters defining the ground-surface heat exchange layer, were more sensitive compared to the deeper layers (coarse sand and gravel, and unfractured bedrock). Sensitivities were also among the highest for the ground-surface heat flux target. High model sensitivity to these parameters highlights the importance of detailed site characterization in the near-surface zone for more realistic simulations of permafrost dynamics.
- Published
- 2020
- Full Text
- View/download PDF
25. Visualization formats of patient-reported outcome measures in clinical practice: a systematic review about preferences and interpretation accuracy
- Author
-
Elaine A. C. Albers, Itske Fraterman, Iris Walraven, Erica Wilthagen, Sanne B. Schagen, Iris M. van der Ploeg, Michel W. J. M. Wouters, Lonneke V. van de Poll-Franse, and Kelly M. de Ligt
- Subjects
Health Information Management ,Data visualization ,Urological cancers Radboud Institute for Health Sciences [Radboudumc 15] ,education ,Systematic review ,Health Informatics ,Patient reported outcome measures ,female genital diseases and pregnancy complications ,Shared decision-making - Abstract
Contains fulltext : 249833.pdf (Publisher’s version ) (Open Access) PURPOSE: The use of Patient-Reported Outcome Measures (PROMs) for individual patient management within clinical practice is becoming increasingly important. New evidence about graphic visualization formats for PROMs scores has become available. This systematic literature review evaluated evidence for graphic visualization formats of PROMs data in clinical practice for patients and clinicians, for both individual and group level PROMs data. METHODS: Studies published between 2000 and 2020 were extracted from CINAHL, PubMed, PsychInfo, and Medline. Studies included patients ≥ 18 years old in daily clinical practice. Papers not available in English, without full-text access, or that did not specifically describe visualization of PROMs data were excluded. Outcomes were: visualization preferences; interpretation accuracy; guidance for clinical interpretation. RESULTS: Twenty-five out of 789 papers were included for final analysis. Most frequently studied formats were: bar charts, line graphs, and pie charts. Patients preferred bar charts and line graphs as these were easy and quick for retrieving information about their PROMs scores over time. Clinicians' interpretation accuracy and preferences were similar among graphic visualization formats. Scores were most often compared with patients' own previous scores; to further guide clinical interpretation, scores were compared to norm population scores. Different 'add-ons' improved interpretability for patients and clinicians, e.g. using colors, descriptions of measurement scale directionality, descriptive labels, and brief definitions. CONCLUSION: There was no predominant graphical visualization format approach in terms of preferences or interpretation accuracy for both patients and clinicians. Detailed clarification of graph content is essential. Patient-Reported Outcome Measures (PROMs) capture patients' self-reported health through the use of questionnaires. PROMs measure health related quality of life, daily functioning, and symptom experience, which are becoming increasingly important to incorporate in clinical practice for individual patient management. To present PROMs within clinical practice, raw or summarized PROMs scores can be visualized in graphical formats. To be useful during clinical encounters, both patients and clinicians ought to interpret such formats correctly. New evidence about graphic visualization formats for PROMs scores has become available. Therefore, we systematically reviewed the literature to evaluate evidence for graphic visualization formats of PROMs data in clinical practice. In 25 included papers, most studies used graphical formats like bar charts, line graphs, and pie charts for presenting PROMs scores. There was no predominant graphical visualization format approach in terms of preferences or interpretation accuracy for both patients and clinicians. Patients preferred bar charts and line graphs as these were easy and quick for retrieving information about their PROMs scores over time. Clinicians’ interpretation accuracy and preferences were similar among graphic visualization formats. The graphical interpretation of PROMs data for patients and clinicians can be improved by using colors, descriptions of measurement scale directionality, descriptive labels, and brief definitions. eng
- Published
- 2022
- Full Text
- View/download PDF
26. Dipolar effects on the work function of an alkali-iodide overlayer (XI, X = Li, Na, K, Rb, and Cs) on tungsten surfaces
- Author
-
L Diaz, R C Albers, A Saxena, and M Sanati
- Subjects
Condensed Matter Physics ,Mathematical Physics ,Atomic and Molecular Physics, and Optics - Abstract
A first-principles approach was used to investigate the effects of alkali metal iodide XI (X = Li, Na, K, Rb, and Cs) adsorption on the work functions of (100), (110), and (111) surfaces of W. For the most energetically stable structures, work functions and their corresponding electric dipole moment vectors were calculated. In agreement with available experimental measurements, it was verified that the formation of XI dipoles on the W surface causes the work function to decrease significantly. It was shown that the calculated XI dipoles are tilted with respect to the W surface for all systems. This contradicts earlier published suggestions that the surface electrostatic energy of the dipoles prevented them from being aligned along the surface and were instead normal to the surface. In our work it is shown that the orientations (tilt) and strengths of the dipole moments can be explained in terms of the internal strain caused by the alkali metal’s different atomic sizes and available surface area. What matters for the decrease in the work function is the component of the dipolar moment perpendicular to the surface. For all systems, the work function reduction was shown to be directly proportional to the normal component of the electric field created by these XI dipoles.
- Published
- 2023
- Full Text
- View/download PDF
27. The Krakatoa Chronicle: An Interactive Personalized Newspaper on the Web.
- Author
-
Tomonari Kamba, Krishna Bharat, and Michael C. Albers
- Published
- 1995
- Full Text
- View/download PDF
28. Albuterol/budesonide for the treatment of exercise-induced bronchoconstriction in patients with asthma: the TYREE study
- Author
-
Craig, LaForce, Bradley E, Chipps, Frank C, Albers, Laurence, Reilly, Eva, Johnsson, Helen, Andrews, Christy, Cappelletti, Andrea, Maes, and Alberto, Papi
- Subjects
Adult ,Cross-Over Studies ,Adolescent ,Bronchoconstriction ,Socio-culturale ,Exercise-induced bronchoconstriction, PT027, albuterol/ICS rescue, albuterol/budesonide ,asthma, inhaled corticosteroids ,asthma ,Bronchodilator Agents ,Exercise-induced bronchoconstriction ,Double-Blind Method ,PT027 ,albuterol/ICS rescue ,Forced Expiratory Volume ,Administration, Inhalation ,albuterol/budesonide ,Humans ,Albuterol ,inhaled corticosteroids ,Budesonide - Abstract
PT027 is a fixed-dose combination of albuterol (salbutamol) and budesonide in a single pressurized metered-dose inhaler.To evaluate the efficacy and safety of albuterol/budesonide compared with placebo in patients with asthma and exercise-induced bronchoconstriction (EIB).In this randomized, double-blind, 2-period, single-dose crossover study, adolescents and adults with asthma and EIB (defined by ≥20% decrease from pre-exercise challenge forced expiratory volume in 1 second [FEVLeast squares mean maximum percentage fall in FEVIn adolescents and adults with asthma and EIB, a single dose of albuterol/budesonide 180/160 µg taken approximately 30 minutes before exercise was significantly more effective than placebo in preventing EIB.ClinicalTrials.gov Identifier: NCT04234464.
- Published
- 2022
29. Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy
- Author
-
Peter H. Howarth, Geoffrey Chupp, Daniel J. Bratton, Steven G. Smith, Frank C. Albers, Guy Brusselle, Linda M. Nelsen, Eric S. Bradford, and Claus Bachert
- Subjects
medicine.medical_specialty ,business.industry ,Immunology ,Eosinophilic asthma ,medicine.disease ,Phenotype ,law.invention ,Clinical trial ,Randomized controlled trial ,Multicenter study ,law ,Internal medicine ,Monoclonal ,Immunology and Allergy ,Medicine ,business ,Mepolizumab ,Asthma ,medicine.drug - Published
- 2020
- Full Text
- View/download PDF
30. Die emotionale Kompetenz der Mutter und die klinische Qualität der Mutter-Kind-Beziehung in einer vorschulpsychiatrischen Inanspruchnahmepopulation
- Author
-
Kathrin Greve, Sandra Achtergarde, Carolin C. Albers, Georg Romer, and Jörg Michael Müller
- Subjects
medicine.medical_specialty ,education.field_of_study ,Population ,Perspective (graphical) ,Moderation ,Emotional competence ,Scale (social sciences) ,medicine ,General Earth and Planetary Sciences ,Emotional expression ,Risk factor ,Psychiatry ,education ,Psychology ,General Environmental Science ,Psychopathology - Abstract
The Emotional Competence of Mothers and the Clinical Quality of Mother-Child Relationship in a Preschool Psychiatric Population The quality of mother-child interaction and relationship is an essential risk factor for the development of mental disorders at preschool age. We examine maternal emotional competence and maternal level of psychopathology as predictors for the quality of mother-child relationship. At the beginning of their treatment a clinical sample of mother-child-dyads at the Child Psychiatric Family Day Hospital in Munster was assessed concerning the emotional competence of mothers (EKF), the maternal psychopathology (SCL) and the mother-child relationship quality, the latter with three different instruments reflecting the mother's, the child's and the therapist's perspective (PIR-GAS, SKEI, M-PCR). The mothers showed decreased results in the EKF scales emotional regulation, recognition of emotions and in the EKF-overall-score and presented a higher level of maternal psychopathology compared to the normal population. There is a direct relation between emotional regulation and the M-PCR scales affective bond and functional-conflict. Besides the direct influence of the maternal psychopathology, the expected moderator effect of emotional expressiveness and the M-PCR scale functional-conflict, reported by mothers, was apparent. Certain aspects of the emotional competence of mothers and their psychopathology show an influence on mother-child relationship quality. The method and the perspective of assessment are crucial to the results.
- Published
- 2020
- Full Text
- View/download PDF
31. Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use
- Author
-
Mark C. Liu, Frank C. Albers, Charlene M. Prazma, Soichiro Hozawa, Marc Humbert, Steven W. Yancey, and Daniel J. Bratton
- Subjects
medicine.medical_specialty ,asthma treatment ,Immunology ,Asthma treatment ,Eosinophilic asthma ,Omalizumab ,Antibodies, Monoclonal, Humanized ,medicine ,Immunology and Allergy ,Humans ,In patient ,biologics ,Anti-Asthmatic Agents ,Pulmonary Eosinophilia ,Letters to the Editor ,Letter to the Editor ,Asthma ,business.industry ,asthma ,medicine.disease ,Dermatology ,eosinophils ,business ,Mepolizumab ,medicine.drug - Published
- 2019
32. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
- Author
-
Dmitry V Galkin, Bradley Chipps, Miguel Bergna, Dalal Mouneimne, Mark C. Liu, Frank C. Albers, Xavier Muñoz, Gilles Devouassoux, Jay Azmi, Kenneth R. Chapman, and Robert Price
- Subjects
Male ,0301 basic medicine ,Exacerbation ,Eosinophilic asthma ,Omalizumab ,Severity of Illness Index ,ACQ‐5 ,Leukocyte Count ,0302 clinical medicine ,Surveys and Questionnaires ,Immunology and Allergy ,Medicine ,Anti-Asthmatic Agents ,Child ,education.field_of_study ,Drug Substitution ,mepolizumab ,Middle Aged ,3. Good health ,Treatment Outcome ,Tolerability ,Asthma Control Questionnaire ,Female ,Original Article ,medicine.drug ,Adult ,medicine.medical_specialty ,Adolescent ,Immunology ,Population ,Antibodies, Monoclonal, Humanized ,Asthma and Lower Airway Disease ,Young Adult ,03 medical and health sciences ,Internal medicine ,Humans ,education ,Aged ,business.industry ,Asthma ,severe eosinophilic asthma ,asthma control ,Eosinophils ,030104 developmental biology ,Standard error ,030228 respiratory system ,Quality of Life ,ORIGINAL ARTICLES ,business ,Mepolizumab - Abstract
Background Mepolizumab and omalizumab are treatments for distinct but overlapping severe asthma phenotypes. Objective To assess if patients eligible for both biologics but not optimally controlled with omalizumab experience improved asthma control when switched directly to mepolizumab. Methods OSMO was a multicenter, open‐label, single‐arm, 32‐week trial in patients with ≥2 asthma exacerbations in the year prior to enrollment, despite receiving high‐dose inhaled corticosteroids and other controller(s), plus omalizumab (≥4 months). At baseline, patients with blood eosinophil counts ≥150 cells/µL (or ≥300 cells/µL in the prior year) and an Asthma Control Questionnaire (ACQ)‐5 score ≥1.5 discontinued omalizumab and immediately commenced mepolizumab 100 mg subcutaneously every 4 weeks. Endpoints included change from baseline in ACQ‐5 score (primary), St George's Respiratory Questionnaire (SGRQ) score and the proportions of ACQ‐5 and SGRQ responders, all at Week 32, and the annualized exacerbation rate over the study period. Results At Week 32 (intent‐to‐treat population [n = 145]), the least squares (LS) mean changes (standard error [SE]) in ACQ‐5 and SGRQ total scores were −1.45 (0.107) and −19.0 (1.64) points; with 77% and 79% of patients achieving the minimum clinically important differences (ACQ‐5: ≥0.5 points; SGRQ: ≥4 points), respectively. The annualized rate of clinically significant exacerbations was 1.18 events/year, a 64% reduction from 3.26 events/year during the previous year. Safety and immunogenicity profiles were consistent with previous trials. Conclusion After directly switching from omalizumab to mepolizumab, patients with uncontrolled severe eosinophilic asthma experienced clinically significant improvements in asthma control, health status, and exacerbation rate, with no tolerability issues reported., Minimal clinically important difference for improvement in asthma control questionnaire‐5 and St. George's Respiratory Questionnaire total scores was achieved by 77% and 79% of patients, respectively. Annualized rate of clinically significant exacerbations was reduced from 3.26 to 1.18 events/year. Safety and immunogenicity profiles of mepolizumab were consistent with previous placebo‐controlled trials in severe eosinophilic asthma.
- Published
- 2019
- Full Text
- View/download PDF
33. Impact of exacerbations on St George’s Respiratory Questionnaire score in patients with severe asthma: post hoc analyses of two clinical trials and an observational study
- Author
-
Necdet B Gunsoy, Hana Müllerová, Frank C. Albers, Linda M. Nelsen, Sarah Cockle, Eric S. Bradford, and Paul W. Jones
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Adolescent ,Health Status ,Severe asthma ,Antibodies, Monoclonal, Humanized ,Severity of Illness Index ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,immune system diseases ,Surveys and Questionnaires ,Eosinophilia ,Humans ,Multicenter Studies as Topic ,Immunology and Allergy ,Medicine ,In patient ,Anti-Asthmatic Agents ,030212 general & internal medicine ,Respiratory system ,Aged ,Randomized Controlled Trials as Topic ,Asthma ,business.industry ,Middle Aged ,Symptom Flare Up ,medicine.disease ,respiratory tract diseases ,Clinical trial ,Observational Studies as Topic ,030228 respiratory system ,Pediatrics, Perinatology and Child Health ,Emergency medicine ,Female ,Observational study ,business ,Mepolizumab ,medicine.drug - Abstract
Objective: To assess the effect of asthma exacerbations and mepolizumab treatment on health status of patients with severe asthma using the St George’s Respiratory Questionnaire (SGRQ).Meth...
- Published
- 2019
- Full Text
- View/download PDF
34. Clinical burden of illness among patients with severe eosinophilic COPD
- Author
-
Dmitry V Galkin, Sarah H. Landis, Hana Müllerová, Frank C. Albers, and Wilhelmine Meeraus
- Subjects
medicine.medical_specialty ,COPD ,Index date ,Exacerbation ,business.industry ,Effective management ,Retrospective cohort study ,General Medicine ,Primary care ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,030228 respiratory system ,Internal medicine ,Eosinophilic ,medicine ,In patient ,030212 general & internal medicine ,business - Abstract
Background: There are currently limited real-world data on the clinical burden of illness in patients with COPD who continue to exacerbate despite receiving triple therapy. The aim of this study was to compare the burden of COPD in patients with and without a phenotype characterized by a high blood eosinophil count and high risk of exacerbations while receiving triple therapy. Methods: This retrospective cohort study (GSK ID: 207323/PRJ2647) used UK Clinical Practice Research Datalink records linked with Hospital Episode Statistics. Eligible patients had a COPD medical diagnosis code recorded between January 1, 2004 and December 31, 2014, and a blood eosinophil count recorded on/after that date. Patients were followed from index date (first qualifying blood eosinophil count) until December 31, 2015. The study phenotype was defined as ≥2 moderate/≥1 severe acute exacerbation of COPD (AECOPD) in the year prior to the index date, current use of multiple-inhaler triple therapy (MITT), and blood eosinophil count ≥150 cells/µL on the index date. Outcomes measured during follow-up included moderate/severe AECOPDs, severe AECOPDs, all-cause mortality, primary care (GP) clinical consultations, and non-AECOPD-related unscheduled hospitalizations. Results: Of 46,814 patients eligible for inclusion, 2512 (5.4%) met the definition of the study phenotype. Adjusted rate ratios (95% CI) of moderate/severe AECOPDs and all-cause mortality in patients with the study phenotype versus those without were 2.32 (2.22, 2.43) and 1.26 (1.16, 1.37), respectively. For GP visits and non-AECOPD-related unscheduled hospitalizations, adjusted rate ratios (95% CI), in patients with the study phenotype versus those without, were 1.09 (1.05, 1.12) and 1.31 (1.18, 1.46), respectively. Conclusion: Patients with COPD and raised blood eosinophil counts who continue to exacerbate despite MITT represent a distinct subgroup who experience substantial clinical burden and account for high healthcare expenditure. There is a need for more effective management and therapeutic options for these patients.
- Published
- 2019
- Full Text
- View/download PDF
35. Visualization formats of patient-reported outcome measures in clinical practice: a systematic review about preferences and interpretation accuracy
- Author
-
Elaine A C, Albers, Itske, Fraterman, Iris, Walraven, Erica, Wilthagen, Sanne B, Schagen, Iris M, van der Ploeg, Michel W J M, Wouters, Lonneke V, van de Poll-Franse, and Kelly M, de Ligt
- Abstract
The use of Patient-Reported Outcome Measures (PROMs) for individual patient management within clinical practice is becoming increasingly important. New evidence about graphic visualization formats for PROMs scores has become available. This systematic literature review evaluated evidence for graphic visualization formats of PROMs data in clinical practice for patients and clinicians, for both individual and group level PROMs data.Studies published between 2000 and 2020 were extracted from CINAHL, PubMed, PsychInfo, and Medline. Studies included patients ≥ 18 years old in daily clinical practice. Papers not available in English, without full-text access, or that did not specifically describe visualization of PROMs data were excluded. Outcomes were: visualization preferences; interpretation accuracy; guidance for clinical interpretation.Twenty-five out of 789 papers were included for final analysis. Most frequently studied formats were: bar charts, line graphs, and pie charts. Patients preferred bar charts and line graphs as these were easy and quick for retrieving information about their PROMs scores over time. Clinicians' interpretation accuracy and preferences were similar among graphic visualization formats. Scores were most often compared with patients' own previous scores; to further guide clinical interpretation, scores were compared to norm population scores. Different 'add-ons' improved interpretability for patients and clinicians, e.g. using colors, descriptions of measurement scale directionality, descriptive labels, and brief definitions.There was no predominant graphical visualization format approach in terms of preferences or interpretation accuracy for both patients and clinicians. Detailed clarification of graph content is essential.Patient-Reported Outcome Measures (PROMs) capture patients' self-reported health through the use of questionnaires. PROMs measure health related quality of life, daily functioning, and symptom experience, which are becoming increasingly important to incorporate in clinical practice for individual patient management. To present PROMs within clinical practice, raw or summarized PROMs scores can be visualized in graphical formats. To be useful during clinical encounters, both patients and clinicians ought to interpret such formats correctly. New evidence about graphic visualization formats for PROMs scores has become available. Therefore, we systematically reviewed the literature to evaluate evidence for graphic visualization formats of PROMs data in clinical practice. In 25 included papers, most studies used graphical formats like bar charts, line graphs, and pie charts for presenting PROMs scores. There was no predominant graphical visualization format approach in terms of preferences or interpretation accuracy for both patients and clinicians. Patients preferred bar charts and line graphs as these were easy and quick for retrieving information about their PROMs scores over time. Clinicians’ interpretation accuracy and preferences were similar among graphic visualization formats. The graphical interpretation of PROMs data for patients and clinicians can be improved by using colors, descriptions of measurement scale directionality, descriptive labels, and brief definitions.
- Published
- 2021
36. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics
- Author
-
Mark C. Liu, Jay Azmi, Gilles Devouassoux, Steven G. Smith, Robert G. Price, Miguel Bergna, Dalal Mouneimne, Bradley E. Chipps, Dmitry V Galkin, Xavier Muñoz, Kenneth R. Chapman, Frank C. Albers, Institut Català de la Salut, [Liu MC] Divisions of Allergy and Clinical Immunology, Pulmonary and Critical Care Medicine, Johns Hopkins Asthma and Allergy Center, Baltimore, MD, USA. [Chipps B] Capital Allergy and Respiratory Disease Center, Sacramento, CA, USA. [Munoz X] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Ciber Enfermedades Respiratorias, Madrid, Spain. [Devouassoux G] Service de Pneumologie, Hôpital de la Croix Rousse, Hospices Civils de Lyon, UCB Lyon, Lyon, France. [Bergna M] Respiratory Research, CEMER, Vicente Lopez, Buenos Aires, Argentina. [Smith SG] Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Male ,Time Factors ,Exacerbation ,Eosinophilic asthma ,Omalizumab ,Other subheadings::Other subheadings::/drug therapy [Other subheadings] ,Severity of Illness Index ,0302 clinical medicine ,Forced Expiratory Volume ,030212 general & internal medicine ,Anti-Asthmatic Agents ,Lung ,Drug Substitution ,Asthma treatment ,Middle Aged ,Treatment Outcome ,Asthma Control Questionnaire ,Disease Progression ,Female ,medicine.drug ,Adult ,medicine.medical_specialty ,terapéutica::farmacoterapia::prescripciones de medicamentos::sustitución de medicamentos [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Asma - Tractament ,Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] ,Biologics ,Antibodies, Monoclonal, Humanized ,03 medical and health sciences ,Diseases of the respiratory system ,Internal medicine ,Post-hoc analysis ,medicine ,Humans ,Therapeutics::Drug Therapy::Drug Prescriptions::Drug Substitution [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,enfermedades respiratorias::enfermedades pulmonares::eosinofilia pulmonar [ENFERMEDADES] ,Pulmonary Eosinophilia ,Eosinofília ,Asthma ,Aged ,RC705-779 ,business.industry ,Research ,diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Recovery of Function ,medicine.disease ,Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Eosinophils ,030228 respiratory system ,Quality of Life ,Avaluació de resultats (Assistència sanitària) ,Respiratory Tract Diseases::Lung Diseases::Pulmonary Eosinophilia [DISEASES] ,business ,Body mass index ,Mepolizumab - Abstract
Background The OSMO study assessed the efficacy of switching to mepolizumab in patients with severe eosinophilic asthma that was uncontrolled whilst receiving omalizumab. The objective of this analysis was to assess the proportion of patients achieving pre-defined improvements in up to four efficacy outcomes and the relationship between patient baseline characteristics and treatment response. Methods This was a post hoc analysis of OSMO study data (GSK ID:204471; ClinicalTrials.gov No. NCT02654145). Patients with severe eosinophilic asthma uncontrolled by high-dose inhaled corticosteroids, other controller(s) and omalizumab subcutaneously (≥ 4 months) were switched to mepolizumab 100 mg administered subcutaneously. Endpoints included the proportion of responders—i.e. patients achieving a pre-defined clinical improvement in ≥ 1 of the following outcomes: (1) Asthma Control Questionnaire (ACQ)-5 score (≥ 0.5-points), (2) St George’s Respiratory Questionnaire (SGRQ) total score (≥ 4-points), (3) pre-bronchodilator forced expiratory volume in 1s (FEV1; ≥ 100 mL), all at Week 32, and (4) annualised rate of clinically significant exacerbations (≥ 50% reduction). Results Of the 145 patients included, 94%, 83%, 63% and 31% were responders for ≥ 1, ≥ 2, ≥ 3 and 4 outcomes, respectively; 75% and 78% were ACQ-5 and SGRQ score responders, and 50% and 69% were FEV1 and exacerbation responders. Subgroup analyses demonstrated improvements irrespective of baseline blood eosinophil count, prior omalizumab treatment regimen/duration, comorbidities, prior exacerbation history, maintenance oral corticosteroid use, ACQ-5 and SGRQ scores, and body weight/body mass index. Conclusions After switching to mepolizumab, almost all patients with uncontrolled severe eosinophilic asthma on omalizumab achieved a beneficial response in ≥ 1 clinical outcome. Improvements were observed regardless of baseline characteristics. Trial registration This manuscript is a post hoc analysis of data from the OSMO study. ClinicalTrials.gov, NCT02654145. Registered January 13, 2016.
- Published
- 2021
37. Personalized, Interactive News on the Web.
- Author
-
Krishna Bharat, Tomonari Kamba, and Michael C. Albers
- Published
- 1998
- Full Text
- View/download PDF
38. Visualization formats of Patient-Reported Outcomes in clinical practice: a systematic review about preferences and interpretation accuracy. (Preprint)
- Author
-
Elaine A. C. Albers, Itske Fraterman, Iris Walraven, Erica Wilthagen, Sanne B. Schagen, Iris M. van der Ploeg, Michel W.J.M. Wouters, Lonneke V. van de Poll-Franse, and Kelly M. de Ligt
- Subjects
education - Abstract
BACKGROUND The use of Patient-Reported Outcomes (PROs) for individual patient management within clinical practice is becoming increasingly important. However, there is no consensus on which graphic visualization format of PRO scores is most suitable. OBJECTIVE This systematic review evaluated evidence for graphic visualization of PROs in clinical practice for patients and clinicians, including preferences, interpretation accuracy, and guidance for clinical interpretation of PRO scores. METHODS We extracted studies published between 2000 and 2020 from CINAHL, PubMed, PsychInfo and Medline. Studies included patients ≥18 years old from daily clinical practice. Papers not available in English, without full-text access or that did not specifically describe PRO visualization were excluded. Outcome measures were: visualization preferences; interpretation accuracy; guidance for clinical interpretation. RESULTS We included 26 out of 789 papers for final analysis. Most frequently studied formats were: bar charts, line graphs and pie charts. Patients preferred bar charts and line graphs as these were easy and quick for retrieving information about their PRO scores over time. Clinicians’ interpretation accuracy was similar among graph formats. Scores were most often compared with patients’ own previous scores; to guide clinical interpretation, scores were compared to norm population scores. Different add-ons improved graph interpretability for patients and clinicians, e.g. using colors, descriptions of measurement scale directionality, descriptive labels and brief definitions. CONCLUSIONS Although we found no predominant format for graphic visualization of PRO scores, straightforward formats like bar charts and line graphs were preferred by both patients and clinicians. Additionally, detailed clarification of graph content is essential.
- Published
- 2021
- Full Text
- View/download PDF
39. Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study
- Author
-
Bradley E Chipps, Frank C Albers, Laurence Reilly, Eva Johnsson, Christy Cappelletti, and Alberto Papi
- Subjects
Pulmonary and Respiratory Medicine ,Adult ,Adolescent ,Socio-culturale ,paediatric asthma ,Asthma ,respiratory tract diseases ,asthma in primary care ,Drug Combinations ,immune system diseases ,Ethanolamines ,Asthma, asthma in primary care, paediatric asthma ,Formoterol Fumarate ,Administration, Inhalation ,Humans ,Albuterol ,Budesonide ,Child - Abstract
IntroductionUncontrolled asthma is associated with substantial morbidity. While fast-acting bronchodilators provide quick relief from asthma symptoms, their use as rescue fails to address the underlying inflammation. Combining a short-acting beta2-agonist, such as albuterol (salbutamol), with an inhaled corticosteroid, such as budesonide, in a single inhaler as rescue therapy could help control both bronchoconstriction and inflammation, and reduce the risk of asthma exacerbations.Methods and analysisThe Phase 3 MANDALA study was designed to determine the efficacy of albuterol in combination with budesonide (albuterol/budesonide 180/160 µg or 180/80 µg, two actuations of 90/80 µg or 90/40 µg, respectively) versus albuterol (180 µg, two actuations of 90 µg) as rescue therapy in adult, adolescent and paediatric patients with moderate-to-severe asthma. This event-driven study enrolled symptomatic patients (3000 adults/adolescents and 100 children aged 4–11 years) who experienced ≥1 severe asthma exacerbation in the previous year and were receiving maintenance therapy for ≥3 months prior to study entry. The primary efficacy endpoint was time-to-first severe asthma exacerbation.Ethics and disseminationThe study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, and that are consistent with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and Good Clinical Practice and the applicable regulatory requirements.Trial registrationNCT03769090.
- Published
- 2021
40. Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
- Author
-
Jo A Douglass, Charlene M. Prazma, Steven W. Yancey, Frank C. Albers, Marco Idzko, Arnaud Bourdin, Stephen Mallett, GlaxoSmithKline [Research Triangle Park] (GSK ), Medizinische Universität Wien = Medical University of Vienna, University Hospital Freiburg, The Royal Melbourne Hospital, University of Melbourne, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), GlaxoSmithKline (GSK), and Herrada, Anthony
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,asthma treatments ,Eosinophilic asthma ,Placebo ,Gastroenterology ,Atopy ,Internal medicine ,Post-hoc analysis ,medicine ,Journal of Asthma and Allergy ,Immunology and Allergy ,biologics ,[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology ,Asthma ,Original Research ,House dust mite ,biology ,business.industry ,[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy ,asthma ,medicine.disease ,biology.organism_classification ,body regions ,allergens and epitopes ,Asthma Control Questionnaire ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,eosinophils ,[SDV.IMM.IMM] Life Sciences [q-bio]/Immunology/Immunotherapy ,business ,Mepolizumab ,[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology ,medicine.drug - Abstract
Purpose Improved understanding of characteristics that may influence treatment response across phenotypes may help guide treatment decisions. Patients and Methods This was a post hoc analysis of MENSA, a multicenter, randomized, double-blind, placebo-controlled trial (NCT01691521). Patients aged ≥12 years with severe eosinophilic asthma received mepolizumab (75 mg intravenously or 100 mg subcutaneously) or placebo, plus standard of care, every 4 weeks for 32 weeks. Outcomes assessed were the annualized rate of clinically significant exacerbations and change from baseline in Asthma Control Questionnaire (ACQ)-5 score. Subgroup analyses were performed by baseline blood eosinophil count (17.5 kU/L]), and by house dust mite (HDM) sensitivity. Results Of 576 patients analyzed, 272 were non-atopic, 181 were atopic and 94 were strongly atopic; 29 had missing atopy data. In patients with blood eosinophil counts ≥300 cells/µL, mepolizumab versus placebo reduced clinically significant exacerbations by 74%, 43% and 25% in the non-atopic, atopic and strongly atopic subgroups. Similar reductions were observed in all atopic subgroups in other blood eosinophil count categories where there were sufficient patient numbers for analysis, except for non-atopic patients with baseline blood eosinophil counts of, Video abstract Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use: https://youtu.be/l92s5nzD3OI
- Published
- 2021
- Full Text
- View/download PDF
41. Electronic correlation induced expansion of Fermi pockets inδ-plutonium
- Author
-
Jian-Xin Zhu, Roxanne Tutchton, G. Kotliar, Wei Ting Chiu, and R. C. Albers
- Subjects
Physics ,Electronic correlation ,Condensed matter physics ,Fermi surface ,02 engineering and technology ,Electron ,021001 nanoscience & nanotechnology ,01 natural sciences ,Brillouin zone ,Character (mathematics) ,Phase (matter) ,0103 physical sciences ,Condensed Matter::Strongly Correlated Electrons ,010306 general physics ,0210 nano-technology ,Wave function ,Fermi Gamma-ray Space Telescope - Abstract
Plutonium is a critically important material as the behavior of its $5f$ electrons stands midway between the metalliclike itinerant character of the light actinides and localized atomic-core-like character of the heavy actinides. The $\ensuremath{\delta}$ phase of plutonium ($\ensuremath{\delta}$-Pu), whereas still itinerant, has a large coherent Kondo peak and strong electronic correlations coming from its near-localized character. Using sophisticated Gutzwiller wave function and dynamical mean-field theory correlated theories, we study the Fermi surface and associated mass renormalizations of $\ensuremath{\delta}$-Pu together with calculations of the de Haas--van Alphen frequencies. We find a large ($\ensuremath{\sim}200%$) correlation induced volume expansion in both the hole and the electron pockets of the Fermi surface in addition to an intermediate mass enhancement. All of the correlated electron theories predict, approximately, the same hole pocket placement in the Brillouin zone, which is different from that obtained in conventional density-functional band-structure theory, whereas the electron pockets from all theories are in, roughly, the same place.
- Published
- 2020
- Full Text
- View/download PDF
42. Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: A meta-analysis
- Author
-
Elisabeth H. Bel, Patrick Mitchell, Frank C. Albers, Njira L Lugogo, Eric S. Bradford, Ian D. Pavord, Steven W. Yancey, Mark C. Liu, Steven G. Smith, and Stephen Mallett
- Subjects
medicine.medical_specialty ,business.industry ,MEDLINE ,Eosinophilic asthma ,Antibodies, Monoclonal, Humanized ,Asthma ,Text mining ,Internal medicine ,Meta-analysis ,medicine ,Immunology and Allergy ,Humans ,In patient ,Anti-Asthmatic Agents ,Pulmonary Eosinophilia ,business ,Mepolizumab ,medicine.drug - Published
- 2020
43. The Wick Sign After Cold Snare Polypectomy: A Case Report
- Author
-
Gregory T Brennan and Gregory C. Albers
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Adverse outcomes ,medicine.medical_treatment ,polypectomy ,General Engineering ,Gastroenterology ,Colonoscopy ,030204 cardiovascular system & hematology ,Polypectomy ,Surgery ,Resection ,03 medical and health sciences ,0302 clinical medicine ,Medical Education ,colonoscopy complications ,colonoscopy ,Cold snare ,Internal Medicine ,Medicine ,business ,030217 neurology & neurosurgery ,Sign (mathematics) - Abstract
Cold snare polypectomy is now the preferred technique for resection of most small colorectal polyps. Endoscopists should be aware of a particular mucosal defect after cold snare polypectomy called the wick sign. The wick sign does not represent residual polyp and is not associated with adverse outcomes. Accurate identification is important to prevent unnecessary intervention. A case is presented here with characteristic findings after polypectomy.
- Published
- 2020
44. Long-term safety and durability of mepolizumab in life-threatening/seriously debilitating severe eosinophilic asthma (SEA): COSMEX
- Author
-
Robert G. Price, Marc Humbert, Stephanie Korn, Sandhya Khurana, Elisabeth H. Bel, JM FitzGerald, Frank C. Albers, Martyn J. Gilson, Eric S. Bradford, G.G. Brusselle, and M Masoli
- Subjects
medicine.medical_specialty ,business.industry ,medicine ,Eosinophilic asthma ,Long term safety ,Intensive care medicine ,business ,Mepolizumab ,medicine.drug - Published
- 2020
- Full Text
- View/download PDF
45. Effectiveness and safety of mepolizumab in real-world clinical practice: The REALITI-A study
- Author
-
Giorgio Walter Canonica, A Maxwell, Kim Gemzoe, Tim Harrison, Frank C. Albers, Shibing Yang, Namhee Kwon, Sandra Joksaite, R OʼReilly, and M.K. Van Dyke
- Subjects
Clinical Practice ,medicine.medical_specialty ,business.industry ,Medicine ,Medical physics ,business ,Mepolizumab ,medicine.drug - Published
- 2020
- Full Text
- View/download PDF
46. Author response for 'Incidence, risk factors and re‐exacerbation rate of severe asthma exacerbations in a multinational, multidatabase pediatric cohort study'
- Author
-
Gino Picelli, Carlo Giaquinto, Miriam C. J. M. Sturkenboom, Frank C. Albers, Robert Suruki, Francesco Lapi, Esmé J. Baan, Elisabeth Svensson, Hettie M. Janssens, Peter R. Rijnbeek, Nada Boudiaf, Marjolein Engelkes, Maria A. J. de Ridder, Melissa K. Van Dyke, Lee Evitt, Eric S. Bradford, Katia M.C. Verhamme, Daniel Prieto-Alhambra, and Sarah Cockle
- Subjects
Pediatrics ,medicine.medical_specialty ,Exacerbation ,business.industry ,Incidence (epidemiology) ,Severe asthma ,Medicine ,business ,Cohort study - Published
- 2020
- Full Text
- View/download PDF
47. Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab
- Author
-
Jean Pierre Llanos, Mark Forshag, Hector Ortega, Monica Kraft, Necdet B Gunsoy, Frank C. Albers, Steven W. Yancey, Andrew Menzies-Gow, and Eric S. Bradford
- Subjects
Male ,Severe asthma ,PERSISTENT ASTHMA ,MULTICENTER ,Peak Expiratory Flow Rate ,AM PEF ,Research & Experimental Medicine ,Gastroenterology ,Leukocyte Count ,DOUBLE-BLIND ,chemistry.chemical_compound ,0302 clinical medicine ,Medicine ,Pharmacology (medical) ,Anti-Asthmatic Agents ,Pharmacology & Pharmacy ,030212 general & internal medicine ,Respiratory system ,General Clinical Medicine ,Morning ,education.field_of_study ,PEAK EXPIRATORY FLOW ,DREAM ,General Medicine ,Middle Aged ,Benralizumab ,Respiratory Function Tests ,Treatment Outcome ,Medicine, Research & Experimental ,Respiratory ,Female ,TRIAL ,Drug Monitoring ,Anti-IL-5 ,Life Sciences & Biomedicine ,medicine.drug ,Adult ,Monoclonal antibody ,medicine.medical_specialty ,Injections, Subcutaneous ,Population ,Antibodies, Monoclonal, Humanized ,Placebo ,03 medical and health sciences ,Double-Blind Method ,Internal medicine ,Post-hoc analysis ,MANAGEMENT ,Humans ,education ,Science & Technology ,business.industry ,BENRALIZUMAB ,Repeated measures design ,EFFICACY ,Asthma ,Lung function ,Eosinophils ,030228 respiratory system ,chemistry ,1115 Pharmacology And Pharmaceutical Sciences ,Blood eosinophils ,business ,Mepolizumab - Abstract
Introduction Previous studies showed that mepolizumab significantly reduces exacerbations and oral corticosteroid use in patients with severe eosinophilic asthma. However, early studies reported inconsistent effects on lung function. This study specifically assessed the onset of clinical effect and the relationship of baseline blood eosinophil count of mepolizumab 100 mg subcutaneous (SC) administration on morning peak expiratory flow (AM PEF). Methods Post hoc analysis of data from two randomized, double-blind, placebo-controlled studies (MENSA, NCT01691521; MUSCA, NCT02281318) of 4-weekly mepolizumab 100 mg versus placebo in patients with severe eosinophilic asthma. Individual study results were generated using a mixed model repeated measures model controlling for multiple covariates and were combined using a fixed effects meta-analysis via inverse-variance weighting. Results Significant improvements in AM PEF after the first dose of mepolizumab 100 mg SC vs. placebo were seen as early as week 1 and continued to improve further with subsequent doses. The mean change in AM PEF was 26 L/min in the mepolizumab group compared to 4 L/min in the placebo group, p
- Published
- 2018
- Full Text
- View/download PDF
48. S2658 Not All AST Elevation Is Pathologic - A Rare Case of Macro-AST in a Healthy Young Female
- Author
-
Robin Zachariah, Gregory C. Albers, James Y. Han, and Shannon Lee
- Subjects
Hepatology ,business.industry ,Rare case ,Gastroenterology ,Elevation ,Physiology ,Medicine ,Young female ,business - Published
- 2021
- Full Text
- View/download PDF
49. Evaluation of the psychometric properties of the St George's Respiratory Questionnaire in patients with severe asthma
- Author
-
Frank C. Albers, Hector Ortega, Sarah Cockle, Linda M. Nelsen, Guy Brusselle, Paul W. Jones, Margaret Vernon, and Steven W. Yancey
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Adolescent ,Psychometrics ,Intraclass correlation ,Injections, Subcutaneous ,Vital Capacity ,Antibodies, Monoclonal, Humanized ,Severity of Illness Index ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Cronbach's alpha ,EQ-5D ,Forced Expiratory Volume ,Surveys and Questionnaires ,medicine ,Humans ,Patient Reported Outcome Measures ,030212 general & internal medicine ,Child ,Aged ,Asthma ,Aged, 80 and over ,business.industry ,Discriminant validity ,Reproducibility of Results ,Middle Aged ,medicine.disease ,humanities ,respiratory tract diseases ,030228 respiratory system ,Asthma Control Questionnaire ,Quality of Life ,Physical therapy ,Administration, Intravenous ,Female ,Patient-reported outcome ,business - Abstract
Purpose Limited data exist on the quantitative validity of the St George's Respiratory Questionnaire (SGRQ) in asthma populations. This study evaluated the psychometric properties of the SGRQ in patients with severe asthma. Methods This was a post-hoc analysis of pooled data from MENSA (N = 576; NCT01691508) and SIRIUS (N = 135; NCT01691521), two randomized, placebo controlled trials of mepolizumab in patients with severe asthma. Patients completed the SGRQ at Baseline and Exit (MENSA Week 32; SIRIUS Week 24). Distributional characteristics, internal consistency reliability, test-retest reliability, convergent and discriminant validity, known-groups validity and responsiveness were assessed. Results Internal consistency reliability was acceptable for the total and domain scores at Baseline and Exit (Cronbach's α was 0.92 and 0.94 at Baseline and Exit, respectively, for the Total score). Test-retest reliability was demonstrated (intraclass correlation coefficients >0.7) for Total score and the Activity and Impacts domains. Convergent and discriminant validity were demonstrated with measures associated or not associated with respiratory-related health status. Known groups validity based on baseline FEV 1 % predicted, Asthma Control Questionnaire (ACQ)-5 score, exacerbations and eosinophil counts was demonstrated for the SGRQ total and domain scores. Responses to therapy based on clinician-rated response, patient-rated response, ACQ-5 change score and exacerbations generally correlated with improvements in SGRQ scores. Conclusions This analysis demonstrated that the SGRQ has acceptable psychometric properties in patients with severe asthma, exceeding the thresholds for adequate reliability, validity and responsiveness. The SGRQ appears to be a good instrument for identifying response to therapy in patients with severe asthma.
- Published
- 2017
- Full Text
- View/download PDF
50. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study
- Author
-
Sarah Cockle, Robert Suruki, Necdet B Gunsoy, Linda M. Nelsen, Eric S. Bradford, Ji-Yeon Shin, Hana Müllerová, and Frank C. Albers
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Endotype ,Adolescent ,Eligibility Determination ,Omalizumab ,macromolecular substances ,Antibodies, Monoclonal, Humanized ,Anti-asthmatic Agent ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Reslizumab ,immune system diseases ,Internal medicine ,Humans ,Immunology and Allergy ,Medicine ,Anti-Asthmatic Agents ,030212 general & internal medicine ,Young adult ,Child ,Aged ,Asthma ,Aged, 80 and over ,business.industry ,musculoskeletal, neural, and ocular physiology ,Middle Aged ,medicine.disease ,respiratory tract diseases ,Cross-Sectional Studies ,nervous system ,030228 respiratory system ,Pediatrics, Perinatology and Child Health ,Immunology ,Female ,business ,Mepolizumab ,medicine.drug - Abstract
Objectives: Severe asthma comprises several distinct phenotypes. Consequently, patients with severe asthma can be eligible for more than one biologic treatment targeting Th2 inflammation, such as anti-interleukin (IL)-5 and anti-immunoglobulin (Ig) E. The objective of this study was to describe treatment eligibility and overlap in treatment eligibility for mepolizumab (anti-IL-5), omalizumab (anti-IgE) and reslizumab (anti-IL-5) in patients with severe asthma, who were recruited from clinical practice. Methods: This cross-sectional, single-visit, observational study in six countries enrolled patients with severe asthma (defined by American Thoracic Society/European Respiratory Society guidelines). Assessable patients were analysed as a total cohort and a sub-cohort, who were not currently receiving omalizumab. Treatment eligibility was defined according to the local prescribing information or protocol-defined inclusion/exclusion criteria. Patients currently receiving omalizumab were automatically categorised as omalizumab-eligible. Results: The total cohort comprised 670 patients who met the analysis criteria, of whom 20% were eligible for mepolizumab, 31–41% were eligible for omalizumab (depending on eligibility criteria used), and 5% were eligible for reslizumab. In patients not currently receiving omalizumab (n = 502), proportions eligible for each biologic were similar (mepolizumab: 20%, reslizumab 6%) or lower (omalizumab 7–21%) than those for the total cohort. Overlap in treatment eligibility varied; in mepolizumab-eligible patients not currently receiving omalizumab (n = 101), 27–37% were omalizumab-eligible and 18% were reslizumab-eligible. Conclusions: Treatment eligibility for mepolizumab and omalizumab was higher than that for reslizumab. Although there was some overlap in treatment eligibility, the patient groups eligible for treatment with anti-IL-5 or anti-IgE therapies were often distinct, emphasising the different phenotypes and endotypes in severe asthma.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.